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Abstract
Purpose of Review Dementia with Lewy bodies (DLB) is a neurodegenerative disease that can be clinically and pathologically
similar to Parkinson’s disease (PD) and Alzheimer’s disease (AD). Current understanding of DLB genetics is insufficient and has
been limited by sample size and difficulty in diagnosis. The first genome-wide association study (GWAS) in DLBwas performed
in 2017; a time at which the post-GWAS era has been reached in many diseases.
Recent Findings DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation atGBA and SNCA. Interestingly,
the GWAS suggested that DLB may also have genetic risk factors that are distinct from those in AD and PD.
Summary Although off to a slow start, recent studies have reinvigorated the field of DLB genetics and these results enable us to
start to have a more complete understanding of the genetic architecture of this disease.
Keywords Dementia with Lewy bodies . DLB . Genetics . GWAS . Next-generation sequencing
Introduction
Dementia with Lewy bodies (DLB) is a neurodegenerative dis-
ease that shares clinical, pathological and genetic features with
Parkinson’s disease (PD) and Alzheimer’s disease (AD). Lewy
body dementia is a term that encompasses both DLB and
Parkinson’s disease dementia (PDD), and the ‘one year rule’
is used to assess the temporal onset of dementia versus parkin-
sonism, in order to differentiate the two diseases. If parkinson-
ism occurs at the same time or within 1 year of dementia, a
diagnosis of DLB is made, whereas if parkinsonism precedes
the onset of dementia by a year or more, PDD is diagnosed. The
fundamental feature of DLB is dementia, which often occurs
with parkinsonism, early fluctuations in cognition and attention,
visual hallucinations and REM sleep behaviour disorder (RBD)
[1••, 2]. Autonomic dysfunction, sleep irregularities, depression
and anxiety are also common. DLB is a devastating disease
because of its symptoms, as well as the fact that there is cur-
rently no cure or disease modifying therapy available.
Furthermore, DLB is thought to have a shorter disease duration
[3] and decreased survival rate compared to AD [4]. The need
to understand the disease pathobiology is imperative for the
development of disease-specific therapies.
It is now clear that DLB has a strong genetic component.
Although most cases are sporadic, a number of reports have
demonstrated the occurrence of the disorder in families
[5–13], in addition to the identification of genetic loci that
modulate risk for the development of DLB [14, 15, 16••].
As such, using common genetic variants, the proportion of
the phenotype that can be attributed to genetic factors was
estimated to be 36% [16••].
DLB Genetics Has Remained Largely Elusive
Despite the fact that we now know that genetics plays a role in
the disease, genes that cause DLB are still to be identified. In
comparison with AD and PD, we know far less about the ge-
netic basis of DLB. There are multiple reasons for this. Firstly,
DLB is difficult to diagnose, as phenotypic overlaps with other
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neurodegenerative diseases can diminish chances of an accurate
diagnosis. The lines between different neurodegenerative dis-
eases can often be blurred, and a patient may show features of
one or several other diseases, both ante and post mortem.
Additionally, DLB is not as frequently recognized as a disease
compared to other well-known disorders, such as AD. Both
factors result in a substantial rate of mis- and under-diagnosis.
This has hindered the collection of large cohorts of cases whose
diagnosis is certain, and as a consequence, has limited large-
scale genetic analyses. Furthermore, as the disease is age-relat-
ed, and typically occurs in those aged 65 or older, the likelihood
of gathering biomaterials from multiple family members for
genetic testing of familial DLB is small. This, coupled with
the fact that families with DLB are rare, has limited the under-
standing ofMendelian DLB genetics. Although still a prevalent
cause of disease in the elderly, DLB is less common than dis-
eases such as AD and PD, and hence cohorts will generally be
smaller for this disease.
Moreover, some previous genetic studies have focused on
Lewy body disease (PD, DLB and PDD) as a whole, and not
specifically to genetic alterations that are unique to DLB
(Table 1). Ultimately, there is less research conducted in
DLB compared to AD and PD (Fig. 1a). DLB was only de-
scribed as a separate disease entity in 1984, comparatively
later than AD or PD (Fig. 1b). Thus, genetic research in
DLB is only just gathering momentum; for example, the first
genome-wide association study (GWAS) in DLB was con-
ducted in 2017 [16••], at a time when we have reached the
post-GWAS era in many diseases. Genetic studies have al-
ready shown that DLB shares genetic risk factors with AD
and PD; however, recent findings suggest that DLB may also
have a unique genetic architecture [16••].
Well-established Genetic Findings in DLB:
APOE, SNCA and GBA
In order to adequately implicate a gene in disease, detailed
assessment of the gene in question is required, with a view
to reproduce findings in independent studies. Replication
studies are fundamental to distinguish true associations from
false positive findings, and thus in the validation of the results
of the initial study [34]. To date, only three genes have been
convincingly established to be involved in DLB: APOE, GBA
and SNCA. Variation in the SNCA gene can modulate risk for
or cause DLB phenotypes. The established risk factors for
DLB are also known to impart risk to either AD (APOE) or
PD (GBA, SNCA). Of note, AD and PD do not share common
genetic risk factors between them [35]. This is in accordance
with a recent study, which showed no evidence of correlation
between PD and AD, but showed that the genetic correlation
between DLB and AD was 0.578 (SE ± 0.075), and between
DLB and PD was 0.362 (SE ± 0.107). The APOE locus is
highly associated with AD and DLB. When removing this
locus from the analysis, the correlation between AD and
DLBwas reduced to 0.332, which does not differ significantly
from the correlation between DLB and PD [36]. It should be
noted that this study used a genotyping array enriched for
neurological disease variants and sowas not entirely unbiased.
SNCA
The SNCA gene was first implicated in DLB when point mu-
tations, p.Ala53Thr and p.Glu46Lys, and locus multiplications
were identified in families with mixed phenotypes of parkin-
sonism and dementia that resembled DLB [37–39]. Locus mul-
tiplications resulting in three copies (heterozygous duplication)
or four copies (homozygous duplication or heterozygous tripli-
cation) of SNCA have been described in PD, PDD and DLB
[39–44], and a comprehensive review of SNCA mutations in
parkinsonism was conducted by Rosborough and colleagues
[45]. Pathogenic mutations in SNCA are very rare, can result
in a wide phenotypic spectrum from PD, PDD, DLB, multiple
system atrophy (MSA) and even frontotemporal dementia
(FTD) [46–49], and can show heterogeneity between members
of the same family in terms of age of onset, phenotype and
pathology. Furthermore, not all duplications are fully penetrant
[41]. SNCA disease-causing point mutations fall in the amphi-
pathic region of alpha-synuclein; however, their role in disease
is not clear, as not all mutations have the same effect. It has been
hypothesized that these mutations may perturb membrane bind-
ing activity, or initiate disease by increasing the propensity of
the protein to aggregate. Triplications result in overexpression
of SNCA mRNA and protein [50], causing a more severe phe-
notype and earlier disease onset.
In addition to causing disease, SNCA has also been shown
to modulate disease risk for DLB and PD. Interestingly, PD
and DLB show differential association profiles at the SNCA
locus, a phenomenon first reported in a study analysing AD
and PD-associated loci in DLB [28]. This difference was also
observed in the recent DLB GWAS (which had some overlap
of samples included in the previous study) [16••]. In detail, the
most associated single nucleotide polymorphism (SNP) at the
SNCA locus in a meta-analysis of GWA studies in Parkinson’s
disease is found 3′ to the gene (rs356182) [51]; this SNP was
not significant in the DLB GWAS, where instead, association
at the SNCA locus is mediated by a SNP 5′ of the gene
(rs7681440). Guella and colleagues also found in a study of
DLB, PD, PDD and healthy controls that the risk for dementia
was associated with a locus located 5′ of the gene, and the risk
for parkinsonismwas associated with variants located 3′ to the
gene [31]. Using GTEx data, it was shown that the rs7681440
SNP is an eQTL for RP11-67M1.1, an antisense gene and a
negative regulator of SNCA expression. The alternative allele
mediates an increase in SNCA expression in the cerebellum
through decreasing expression of the SNCA repressor [16••],
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which would fit with a mechanism of increased SNCA expres-
sion increasing risk for disease, although further studies are
required to confirm this hypothesis.
Interestingly, the most significantly associated SNP in
SNCA in DLB was shown to be in linkage disequilibrium
(LD) with a SNP in PD that was significantly associated with
the disease once the most significant SNP was removed [51].
SNCA methylation was suggested to be significantly de-
creased in DLB [52], albeit in a small study of 20 clinical
DLB cases and 20 controls. Differential expression of SNCA
Fig. 1 Number of publications and important landmarks in Dementia
with Lewy bodies. a Number of research publications in Alzheimer’s
disease, Parkinson’s disease and dementia with Lewy bodies from 1995
to 2017. Research publications are far fewer in dementia with Lewy
bodies as compared to Alzheimer’s or Parkinson’s diseases. The terms
‘Alzheimer’s disease’, ‘Parkinson’s disease’ and ‘Dementia with Lewy
bodies’ were used as input for PubMed and the resulting number of
publications per year were plotted. The time points begin in 1995, when
DLB was first established as a disease entity. b Timeline of important
landmarks in dementia with Lewy bodies. Parkinson’s and Alzheimer’s
disease were proposed as disease entities many years before the
establishment of DLB as a disease (1817, 1906 versus 1976); however,
cortical Lewy bodies were identified in 1960. The first diagnostic criteria
for DLB were established in 1996, and updated in 2005 and 2017. This
timeline has been created using the historical landmarks for DLB from
Kenji Kosaka’s chapter (chapter 1), in his recent book [33]. PD =
Parkinson’s disease, AD = Alzheimer’s disease, DLB = dementia with
Lewy bodies
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isoforms in DLB have been proposed [52, 53], but requires
further study due to small sample sizes. A systematic review
concluded that DLB patients have decreased alpha-synuclein
in CSF and this may be used to differentiate these patients
from AD, but not PD cases [54].
REP1 is a polymorphic microsatellite repeat upstream of
the SNCA translation start site. Variations in REP1 length have
been associated with PD [55], and PD-associated REP1 poly-
morphisms enhance SNCA transcription in transgenic mice
[56]. It was later shown that a SNP in SNCA identified to be
associated with PD in a GWAS (rs3857059) is in LD with the
REP1 risk allele (D′ = 0.872, R2 = 0.365) [57]; however, in a
separate, albeit small study, REP1 was not associated with PD
[31]. So far, it is not known whether REP1 polymorphisms are
involved in DLB, given that this has not been tested
specifically.
The SNCA gene is highly relevant to synucleinopathies as
its encoded protein, alpha-synuclein, aggregates within neu-
rons to form Lewy bodies and Lewy neurites [58], which are
the pathological hallmark of PD, PDD and DLB. The anatom-
ical distribution of Lewy-related pathology is often wide-
spread to limbic and neocortical areas in DLB and PDD, and
at end stage, the diseases are indistinguishable. The presynap-
tic aggregation of alpha-synuclein is thought to cause neuro-
degeneration in DLB [59], where it has been shown to be
phosphorylated [60]. Alpha-synuclein aggregation in neuro-
degenerative diseases not only differs in the brain regions
affected, but also the cell types in which it is found, for exam-
ple, the aggregation of alpha-synuclein in glial cytoplasmic
inclusions (GCI) is typically seen in multiple system atrophy
(MSA). A recent study demonstrated that the alpha-synuclein
species in GCIs and LBs are conformationally and biological-
ly distinct [61•]. Lewy-related pathology can also been seen as
a secondary pathology in Alzheimer’s disease [62], predomi-
nantly in the amygdala [63].
APOE
Genetic variation at two SNPs (rs429358 and rs7412) in the
APOE gene result in three alleles, of which the ε4 allele is well
established to increase the risk of developing Alzheimer’s
disease in a dose-dependent manner [64, 65]. APOE ε4 allele
dosage has also been shown to be a risk factor for the devel-
opment of DLB, and whilst first identified over 20 years ago
[14], has since been replicated in a number of studies [3, 16••,
27–30, 66].The protective effect of the ε2 allele is less well
established in DLB, conferring protection in some studies [67]
but not others [3]. DLB patients who carry ε4 alleles die at a
younger age than those who do not [30]. It was hypothesized
that the association of APOE ε4 in DLB may be driven by the
presence of AD-related neuropathology [68], which can often
be seen alongside Lewy-related pathology in DLB brains.
However, the association with APOE ε4 remains robust in
‘pure’ DLB cases who have Lewy bodies but minimal or
low-level Alzheimer-related pathology [66], perhaps suggest-
ing that APOE is correlated to dementia in a mechanism un-
related to the amyloid cascade. Interestingly, APOE is not a
risk factor for PD [69], which demonstrates its specificity for
dementia risk. Furthermore, a recent study showed that APOE
ε4 dose was associated with decreased hippocampal volumes
irrespective of AD or DLB diagnosis [70].
APOE encodes apolipoprotein E, a protein that is involved
in lipid binding, transport and receptor-mediated endocytosis
[71] and that is suggested to influence AD pathogenesis
throughmechanisms related to amyloid beta (Aβ) aggregation
and clearance. However, other possible pathological processes
involving tau phosphorylation, neuroplasticity and neuroin-
flammation have been proposed [72].
APOE alleles differ in CpG content and in ε3/ε4 genotype
carriers, APOE CpG island methylation was significantly de-
creased in the frontal lobe of AD and DLB patients, with the
most significant decrease in DLB patients with mixed AD and
LB pathology, as compared to pure AD or LB pathology cases
[73]. Although further studies are required to replicate this
finding, and to analyse differential methylation of other
APOE genotypes in DLB, this may suggest that epigenetic
changes at this locus play a role in disease etiology.
GBA
Homozygous mutations in the GBA gene cause Gaucher dis-
ease (GD); through astute clinical observation, it was noted
that some GD patients showed parkinsonian features [74], and
that heterozygous carriers of these variants had a higher prev-
alence of PD [75], leading to the discovery that heterozygous
variants inGBA can predispose to PD, with an odds ratio (OR)
of 5.43 (95% CI, 3.89–7.57) [76]. This was also shown to be
true for DLB [15, 16••, 27, 30, 77–83], with an OR of 8.28
(95% CI, 4.78–14.88), where GBA variants are linked to ear-
lier disease onset and death [15].
PD patients with GBA variants have an approximate 2.4-
fold increased incidence of cognitive impairment [84] and,
given the increased OR for DLB, suggests a strong affinity
of GBA variants for Lewy body dementia. Whilst a role for
variants in GBA in DLB disease risk modulation has been
unequivocally established, the role of specific variants in
DLB pathogenesis is less clear, due to disparities between
studies in classification of GBA variants (analysis restricted
to GD variants or also including other rare variants), and dif-
ferential coverage of the gene (genotyping or whole gene se-
quencing). Furthermore, some studies do not analyse the
p.Glu365Lys variant, as it does not cause GD when homozy-
gous and only reduces enzyme activity by approximately half
[85]. Nevertheless, p.Glu365Lys is associated with PD, and is
thought to explain the genome-wide signal at the SYT11-GBA
locus [86]. This may also be the case for DLB, as the strongest
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association at the GBA locus was in strong LD with
p.Glu365Lys (D′ = 0.9, R2 = 0.78).
Mutations inGBA reduce activity of its lysosomal enzyme,
β-glucocerebrosidase (Gcase), and Gcase activity has been
shown to be reduced in sporadic PD brains without GBA mu-
tations, due to decreased amount of protein [87]. Interestingly,
Gcase deficiency can be detected in the CSF of PD patients,
irrespective of mutation carrier status [88], providing promise
for use as a biomarker in PD. It is hypothesized that decreased
Gcase activity leads to impaired degradation of alpha-
synuclein within the lysosome, resulting in its accumulation.
In turn, increased alpha-synuclein perturbs Gcase transport to
lysosome, therefore furthering lysosomal dysfunction [89].
Thus far, most studies have analysed Gcase deficiency in
PD, and it is not known whether the same occurs in DLB.
Nevertheless, Gcase was also significantly reduced in DLB
CSF in a small study comparing DLB, AD, FTD and controls
[90], suggesting its potential use as a biomarker for disease.
GWAS
The first DLB GWAS was conducted in late 2017, and incor-
porated a total of 1743 DLB patients (1324 of which had
autopsy supported diagnosis) and 4454 controls [16••].
Genotyping data was enriched with SNPs imputed from the
haplotype reference consortium, to allow detection of lower
frequency variants. SNCA, GBA and APOE loci were signifi-
cantly associated with DLB in the discovery and replication
phases, as well as the meta-analysis of both stages. In the
discovery phase, two other loci were genome-wide signifi-
cant: BCL7C/STX1B (OR 0.74, 0.67–0.82; p = 3.30 ×
10−9) and GABRB3 (OR 1.34, 1.21–1.48; p = 2.62 ×
10−8). However, the GABRB3 signal did not maintain signif-
icant association when restricting analysis to pathologically
diagnosed samples (p = 1.21 × 10−7). Loci with p <
5 × 10−6 were genotyped in the replication phase, and
CNTN1, a locus that reached suggestive association in the
discovery phase (OR 1.58, 1.32–1.88; p = 4.32 × 10−7,
pathologically diagnosed cases only), was significantly asso-
ciated in the replication phase (p < 0.05). As CNTN1 lies <
500,000 bp away from the LRRK2 locus, samples that
harboured the p.Gly2019Ser LRRK2 variant were removed
from analysis, without significant effect on the association at
CNTN1. However, whether other LRRK2 variants may medi-
ate the association cannot be ruled out. BCL7C/STX1B was
genome-wide significant in the meta-analysis; however, this
was mainly driven by the discovery phase, and requires fur-
ther replication. Despite the identification of interesting can-
didates, replication of novel associations is required, and fur-
ther GWA studies with larger cohorts are warranted.
Heritability was shown to be higher than expected given chro-
mosome size on chromosomes 19, 5, 6, 7 and 13 but apart
from chromosome 19, no genome-wide significant variants
were identified, suggesting that, perhaps, other DLB genes
may be present on these chromosomes.
Studies in Familial Forms of DLB
Although not particularly common, several DLB families have
been studied, but these have failed to shed much light on the
genetics of the disease. Only a small proportion of patients
within these families underwent genetic analysis, and if per-
formed, it was usually minimal with very few cases assessed
at the exome or genome levels. As mentioned above, variation
in SNCA sequence or dosage has been identified in families as
the cause of mixed PD and DLB phenotypes. Some DLB pa-
tients have a family history of neurodegenerative disease, but
not necessarily of DLB, with family members being diagnosed
with AD or PD. Alzheimer families with mutations in APP,
PSEN1 and PSEN2 have been described with phenotypes of
mixed parkinsonism and dementia suggestive of DLB [91–93],
and extensive Lewy body pathology has also been found in
Alzheimer’s families with these mutations [94, 95], suggestive
of a possible mechanistic link. Indeed, DLB cases frequently
present Aβ pathology at autopsy [96], and it has been suggested
that Aβ accumulation can trigger Lewy body disease [97]. A
recent review by Vergouw and colleagues [98] provides a sum-
mary of familial studies in DLB. The most promising study to
identify a novel DLB gene relied on linkage analysis in a DLB
family which identified a locus on chromosome 2q35-q36 [11];
however, no gene was subsequently identified [99]. This could
be because the variant was not detectable with current technol-
ogy or, perhaps, the linkage results were misleading.
As our knowledge of the disease progresses, the diagnostic
criteria for DLB are updated (Fig. 1b) to provide increasing
sensitivity and specificity for accurate diagnoses [1••]. It is
also worth considering whether previous reports in DLB fam-
ilies, which occurred when the first consensus criteria were in
use, have patients that would meet current diagnostic criteria
for DLB. The lack of autopsy data in some of these studies
makes a reliable diagnosis difficult. Moving forward, genetic
analysis of multiple family members with well characterized
clinical and autopsy data that meet more recent diagnostic
criteria for DLB, will be paramount in identifying novel
disease-causing genes.
Genes Causative of Other Neurodegenerative
Diseases
As DLB may clinically and pathologically resemble
Alzheimer’s or Parkinson’s diseases, speculation as to wheth-
er AD- or PD-causing genes may also be involved in the
pathogenesis of DLB prompted the study of these genes in
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small cohorts of mainly sporadic DLB cases. However, due to
the phenotypic similarities between diseases, it is still unclear
whether the mutations identified play a role in DLB or simply
occur in misdiagnosed cases. This issue is complicated further
by the heterogeneity of phenotype that can be associated with
some of these mutations [41, 46–48, 91, 93, 100].
Mutations that are established to be pathogenic in APP and
PSEN1 were found in either a clinical DLB case [29]; or in
pathologically confirmed DLB cases, of which 69% of the
cohort also met pathological criteria for Alzheimer’s disease
[27]. Furthermore, studies of genes that cause other neurode-
generative diseases have identified variants in DLB patients
that have been previously reported, but are of unknown path-
ogenic consequence in genes such as CHMP2B, SQSTM1,
PSEN2 [30] and GRN [29]. Novel variants in MAPT [29]
and multiple variants of uncertain significance have also been
reported. A compound heterozygous mutation in PARK2 was
identified in a DLB patient [30]; however it is unclear whether
the data was phased. Rare variants inGRN were hypothesized
to be associated with DLB, albeit in a very small study of 58
DLB cases and 380 controls [32]. Nevertheless, if the reported
mutation carriers do in fact have DLB, mutations in genes
known to cause Mendelian forms of other neurodegenerative
diseases only occur in a small proportion of DLB cases.
Other Findings
The MAPT H1G sub-haplotype was associated with clinical
DLB; however, the association was attenuated when patho-
logically diagnosed samples were included in analysis [24],
weakening evidence for a role specific to DLB. The H1 hap-
lotype may be associated with more severe alpha-synuclein
deposition, as suggested in a small study of 22 DLB brains
[101].MAPT p.Ala152Thr has been proposed to be associated
with DLB in a clinical DLB cohort [25]. This variant is also
associated with AD and FTD-spectrum disorders [102], but
not PD [25, 102]. However, the MAPT locus showed no evi-
dence of association in the DLB GWAS [16••], and this is of
interest as theMAPT locus is a highly significant result in PD,
reaching genome-wide significance even in smaller studies of
approximately the same number of cases as the DLB GWAS
[103]. Therefore, there is limited convincing evidence for a
role of MAPT variation in DLB, and further studies of risk
associated haplotypes in larger cohorts are needed.
Variants in the TREM2 gene confer a risk for the develop-
ment of AD similar to that associated to one ε4 allele of
APOE, an association mediated primarily by the p.Arg47His
variant, but also by others, such as p.Arg62His. The
p.Arg47His variant was not found to be associated with
DLB [16••, 22]; however, in a small study of 58 DLB cases,
p.Arg62His was nominally associated with DLB (uncorrected
p value = 0.0024, OR = 3.2 [95% CI 1.7–27] [32], although
this would not survive multiple-test correction. Again, further
study is required to identify the role, if any, of TREM2 in DLB.
Pathogenic hexanucleotide repeat expansions in the
C9ORF72 gene are the most common cause of FTD and/or
ALS. Analysis of the expansion in neuropathologically diag-
nosed DLB patients found three cases with either 32 or 33 re-
peats, in a combined total of 1562 patients [17, 19, 104]; whereas
studies of clinically diagnosed DLB patients have identified two
patients with > 30 repeats [18, 19, 105]. This suggests that repeat
expansions in C9ORF72 are not a common cause of DLB.
An increased frequency of the LRRK2 p.Gly2019Ser variant
was seen in DLB compared to controls (0.0021 versus 0.0003,
respectively) [16••]; however, this was not statistically assessed
given its low frequency. This variant has previously been seen in
a clinical DLB case [26], and in two Ashkenazi Jewish individ-
uals with DLB [80], demonstrating a low frequency in this dis-
ease.Where studied, no other pathogenic LRRK2mutationswere
found in DLB cases [27, 29, 30], and no LRRK2 variants were
significantly associated with DLB [26]. Whilst LRRK2 genetic
variation does not seem to occur often in DLB, it is difficult to
distinguish between PD, PDD and DLB and thus assess the
contribution of LRRK2 specifically to DLB [106]. LRRK2 mu-
tation carriers in PD have a lower rate of dementia [107], perhaps
providing further evidence against a role in DLB.
The apparent lack of association for other strong AD and
PD risk loci, such as TREM2, MAPT, CLU, PICALM, and
BIN1 may hint at distinct genetic features for DLB, or may
be attributed to insufficient power to detect associations.
Requirements for Future DLB Genetic Studies
Genetic research in DLB is only just beginning to come to-
gether, providing hope for future characterization of the ge-
netic architecture of the disease. In order to identify additional
genes implicated in DLB, it will be imperative to study more
individuals with the disease. This will require collaborative
approaches in order to increase cohort numbers and more
studies that are focused on replicating results. As well as gen-
erating genetic data, it is important to collect detailed clinical
and pathological data on patients studied.
There is a clear need for more unbiased genetic studies (ge-
nome- or exome-wide). The majority of genetic studies in DLB
thus far have been hypothesis based, largely trying to identify
candidate genes (Table 1). Table 1 also highlights the fact that
some DLB samples have been used in multiple genetic studies,
an event that should be made clear and that can severely bias
results, certainly for a disease where sample collections are small.
Large-scale genetics studies in neurodegenerative diseases
have been dominated by European and American cohorts. The
study of patients from other populations could allow the dis-
covery of population-specific, predisposing variants, which in
turn may provide novel insights into the biological processes
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that occur in disease. DLB research in Japan has been invalu-
able for furthering our understanding of the disease. For in-
stance, the earliest identification of DLB patients [108], and
the study of [(123)I]MIBG myocardial scintigraphy to distin-
guish DLB [109], were first proposed by Japanese scientists.
Detailed, large-scale genetic analyses of these patients could
be transformative for the field.
Conclusion
Understanding the genetic bases of a disease can allow us to
identify pathways and mechanisms involved in the disease
pathobiology. An example of this is in AD, where the identi-
fication ofAPP, PSEN1 andPSEN2mutations were crucial for
the development of the amyloid cascade hypothesis.
Furthermore, genetics may be able to help us tease apart PD,
AD, DLB and PDD using molecular data. As diagnostic
criteria [1••] and understanding of the disease improves
[110–112], we will be able to have a better understanding of
the biological processes underlying DLB, and this may lead to
the identification of disease-specific therapeutic targets.
Next-generation sequencing technology has revolutionized
genetic analysis, and in combination with large-scale databases
of genetic variation such as gnomAD or ExAC [113], has
allowed us to have a better understanding of genetic variation
in humans. This knowledge is going to improve as datasets
increase—the 1000 Genomes Project, which began in 2008,
included whole genome data from 2504 individuals [114], yet
current databases such as ExAC and gnomAD [113], now pro-
vide data from 60,706 exomes or 123,136 exomes and 15,496
genomes, respectively. Although these types of datasets will
include information from individuals who will suffer from neu-
rodegenerative disease, they have been invaluable in informing
the evaluation of potentially pathogenic variants [115].
Furthermore, improved interpretation of GWAS results will en-
able genetic variants to be linked to a functional role in disease
risk [116]. In addition, polygenic risk scores can be used to
calculate an individual’s lifetime risk for disease based on their
genetic profile, a process that has already been implemented in
Alzheimer’s and Parkinson’s diseases [117, 118], and that may
allow for identification of presymptomatic individuals.
The role for genetics in human biology is multifaceted and
complex, and thus we need to integrate DNA sequencing, with
RNA and protein expression, tissue and cell-specific expression
and epigenetic analyses in order to reveal as complete a picture
as possible. The overall objective is to understand the pathways
that are perturbed in disease and that should be therapeutically
targeted. Therapies will likely need to be administered prior to
clinical disease onset, and therefore must target the prodrome.
Genetic studies may allow us to identify those particularly sus-
ceptible for the development of the disorder, by utilizing poly-
genic risk scores or causative mutations.
Moreover, genetics has informed the use of biomarker: by
associating genes with disease, there is the potential to analyse
the proteins encoded by those genes in patients in order to aid
diagnosis. For example, it has been suggested that Gcase [90]
or alpha-synuclein [54] levels may be altered in the CSF of
DLB patients. A recent study identified phosphorylated alpha-
synuclein in skin biopsies of DLB patients, which was absent
in controls, or those with an alternative diagnosis of dementia
[119]. Although requiring replication, phosphorylated alpha-
synuclein in skin was suggested to contribute to autonomic
dysfunction and may provide an easy and relatively inexpen-
sive biomarker for DLB [120].
Although DLB genetic research is still only in its begin-
ning, interest in this area has increased, resulting in the iden-
tification of several genes that are involved in the disease. This
is the first step to obtain a complete picture of the genetic
architecture of DLB. As we get closer to this stage, we will
be able to better understand disease pathogenesis and to nom-
inate candidate disease-specific therapeutic targets, which will
enable us to slow, or even halt, this devastating disease.
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